Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 910 JPY -0.47% Market Closed
Market Cap: 4.8T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Otsuka Holdings Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Depreciation & Amortization
ÂĄ107.9B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
7%
Takeda Pharmaceutical Co Ltd
TSE:4502
Depreciation & Amortization
ÂĄ758.5B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
Depreciation & Amortization
ÂĄ64.4B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
6%
S
Shionogi & Co Ltd
TSE:4507
Depreciation & Amortization
ÂĄ19.7B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
3%
Chugai Pharmaceutical Co Ltd
TSE:4519
Depreciation & Amortization
ÂĄ31.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Depreciation & Amortization
ÂĄ184.9B
CAGR 3-Years
36%
CAGR 5-Years
23%
CAGR 10-Years
11%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.8T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.

Intrinsic Value
9 473.82 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
107.9B JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Depreciation & Amortization amounts to 107.9B JPY.

What is Otsuka Holdings Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
7%

Over the last year, the Depreciation & Amortization growth was 14%. The average annual Depreciation & Amortization growth rates for Otsuka Holdings Co Ltd have been 9% over the past three years , 9% over the past five years , and 7% over the past ten years .

Back to Top